Drug discovery and development for neglected parasitic diseases.
about
Ascaris suum draft genomeNerolidol: A Sesquiterpene Alcohol with Multi-Faceted Pharmacological and Biological ActivitiesNematode phospholipid metabolism: an example of closing the genome-structure-function circleDrug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screeningVinyl Sulfones as Antiparasitic Agents and a Structural Basis for Drug DesignComparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruziNovel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteasesNonpeptidic Tetrafluorophenoxymethyl Ketone Cruzain Inhibitors as Promising New Leads for Chagas Disease ChemotherapyStructural Basis for Inhibition of Cathepsin B Drug Target from the Human Blood Fluke, Schistosoma mansoniEvolution of Structure and Mechanistic Divergence in Di-Domain Methyltransferases from Nematode Phosphocholine BiosynthesisAdvances in Development of New Treatment for LeishmaniasisA comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoniMIRO and IRbase: IT tools for the epidemiological monitoring of insecticide resistance in mosquito disease vectorsMining a cathepsin inhibitor library for new antiparasitic drug leadsA screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hitNaphthoquinone derivatives exert their antitrypanosomal activity via a multi-target mechanismMolecular changes in Opisthorchis viverrini (Southeast Asian liver fluke) during the transition from the juvenile to the adult stageA global comparison of the human and T. brucei degradomes gives insights about possible parasite drug targetsUtilizing a dynamical description of IspH to aid in the development of novel antimicrobial drugsTrypanothione reductase: a target protein for a combined in vitro and in silico screening approachBeyond phage therapy: virotherapy of protozoal diseasesScaffold proteins LACK and TRACK as potential drug targets in kinetoplastid parasites: Development of inhibitorsDrug discovery and the use of computational approaches for infectious diseases.Lessons learnt from assembling screening libraries for drug discovery for neglected diseases.RNA interference of Trypanosoma brucei cathepsin B and L affects disease progression in a mouse model.Development of a novel virtual screening cascade protocol to identify potential trypanothione reductase inhibitors.Two approaches to discovering and developing new drugs for Chagas disease.Repositioning of an existing drug for the neglected tropical disease Onchocerciasis.Discovery of novel benzoxaborole-based potent antitrypanosomal agents.New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugsFacile Synthesis and Preliminary Structure-Activity Analysis of New Sulfonamides Against Trypanosoma bruceiIdentification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis.Optimisation of the anti-Trypanosoma brucei activity of the opioid agonist U50488Structural and evolutionary divergence of eukaryotic protein kinases in Apicomplexa.Parasite-based screening and proteome profiling reveal orlistat, an FDA-approved drug, as a potential anti Trypanosoma brucei agent.Expression profile of the Schistosoma japonicum degradome reveals differential protease expression patterns and potential anti-schistosomal intervention targets.The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases.Target assessment for antiparasitic drug discovery.In vitro anti-Toxoplasma gondii activity of root extract/fractions of Eurycoma longifolia Jack.Discovery and structure-activity relationships of pyrrolone antimalarials.
P2860
Q22122174-510C9F06-FB38-4B7A-83DB-CA5DA733B63FQ26748306-30B7451E-E6E4-438A-A1EC-CD3B87DF2D75Q26853143-511B0505-FE92-4D3D-A9B1-35BD6AC99A4FQ27306843-48E2641C-C9CC-454E-81DE-E223D0CB1DE1Q27646557-68C8F811-B555-4C7E-BA59-BCDC2784C632Q27657406-FB90C722-EA7B-44A8-8C02-F555FBAC3404Q27657523-4E7B26D9-13FE-4A42-BAE3-2AF190C74590Q27659045-FB84ED72-0409-41C5-88A3-F1E8D0AC1B6FQ27671668-2A1D319B-FA70-4D5B-90F1-D33EAF9A90BDQ27679882-C5E12368-853E-42E7-AD30-E3C07C7842FCQ28082097-366C04D7-D471-47C0-AE5C-32DFB167ACB6Q28474728-0172CE8E-550E-487C-BDFB-039F88E35B99Q28475614-1F0E589F-94B9-49BA-8A74-CEFFB3EDD5FCQ28478016-4CD26ACD-A713-49C3-A231-1F7630A21A8EQ28479211-B884913E-D4D5-4C93-A466-15A631E2CB44Q28485165-CAD0CBF8-3913-4724-80EF-3FD42A56779EQ28485368-83979FDD-AC81-4A9F-98FB-C92ED6906618Q28485518-0684EF20-E98A-4921-9087-67871824435EQ28537776-22C4ED00-FFD2-4B4A-9296-62E90AE69F68Q28547882-4CC077E9-6DE4-4E34-93F0-5C7090DD6D20Q29396924-BE7EA43C-4DF6-4318-9C87-9A46FFE14790Q30359734-C5926267-FB16-4929-A2E0-A46E6DAFF9E6Q30404272-82176337-1DB9-4E7B-9B44-49F694B6D384Q33309109-77C24EE2-5BE4-4CFC-B49C-E1ADF2DF33A2Q33372345-E417DDAA-354C-4813-93D2-4793C8B0A587Q33419478-5366B37A-E30F-41A1-901A-C33932057594Q33503274-283C9F7D-6C17-4AD3-9DD2-5A2B62CA66B7Q33530297-6933ADAF-80B1-4078-93C2-F0C55FDD2EFCQ33557952-040ADFD8-5700-4FE0-A4E9-52C874B36FC6Q33622982-4DFF86DA-069C-4639-9DE0-BE1B44FD0266Q33636542-C187A485-77E9-42B0-9F36-68A62C58A4ABQ33653056-F1FDAA3D-F685-455C-9BC1-E6AE88726061Q33990598-69461FD7-3C24-4138-9420-E29E7C239AD2Q34065070-2501BDFF-09E3-4125-AFE2-990EF1630AE9Q34279501-22E696CA-ADF9-4D7A-AE43-BD566F182029Q34281731-D9F9783B-4779-482C-B00F-A371E5A5CBDBQ34286572-8F7CD658-C68D-4A8A-9516-4DABEC3E3707Q34301994-1B68242B-C877-4751-8A9C-014D8213D0F1Q34332413-1D443E99-05BB-4B68-8DDD-A48B3C5B3B46Q34630875-EA390970-7113-4734-A86B-B9982C35DC67
P2860
Drug discovery and development for neglected parasitic diseases.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Drug discovery and development for neglected parasitic diseases.
@ast
Drug discovery and development for neglected parasitic diseases.
@en
type
label
Drug discovery and development for neglected parasitic diseases.
@ast
Drug discovery and development for neglected parasitic diseases.
@en
prefLabel
Drug discovery and development for neglected parasitic diseases.
@ast
Drug discovery and development for neglected parasitic diseases.
@en
P2860
P356
P1476
Drug discovery and development for neglected parasitic diseases.
@en
P2860
P2888
P304
P356
10.1038/NCHEMBIO837
P577
2006-12-01T00:00:00Z